Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Carcinoma 1

Interventions

Radiotherapy 11Cisplatin 11Radiotherapy, Intensity-Modulated 6Radiation 5Fluorouracil 5Cetuximab 5pembrolizumab 4Carboplatin 3fludarabine phosphate 2fludarabine 2durvalumab 2aldesleukin 2Vorinostat 2Surveys and Questionnaires 2Restraint, Physical 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Paclitaxel 2Nivolumab 2Nicotine 2Immunohistochemistry 2Hydroxyurea 2Gene Expression Profiling 2Drug Therapy 2Docetaxel 2Cyclophosphamide 2Counseling 2Celecoxib 2Bupropion 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Oropharyngeal Neoplasms × (225)Ac-DOTA-c(RGDyK) × Clear all
NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡